A study evaluating the safety, tolerability, and pharmacokinetics of single and multiple oral doses of SUVN-502 in healthy young adults.

Trial Profile

A study evaluating the safety, tolerability, and pharmacokinetics of single and multiple oral doses of SUVN-502 in healthy young adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs SUVN 502 (Primary)
  • Indications Alzheimer's disease; Schizophrenia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms FIH study
  • Most Recent Events

    • 02 Feb 2018 New trial record
    • 29 Jan 2018 Results published in the Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top